MYC and Miyoshi myopathy: Interestingly, it has been shown that triple-relapsed MM compared to newly diagnosed or relapsed samples pre-daratumumab exposure [50], and extramedullary MM compared to newly diagnosed MM [51] upregulate E2F and MYC targets as well as the G2/M checkpoint gene set, further underscoring the association between ADAM8/9/15 upregulation and disease progression.